The peroxisome proliferator-
activated receptor-
γ (PPARγ) is the nuclear receptor responsible for transducing the therapeutic activity of the thiazolidinediones (TZDs). TZDs are a group of structurally related synthetic PPARγ receptor agonists with antidiabetic actions
in vivo.
1,2 There are many PPARγ agonists, including 15-
deoxy-
Δ
12,14-
prostaglandin J
2 and azelaoyl PAF, which are naturally derived.
3,4 However, only a few antagonists have been reported.
5 T0070907 is a potent and selective antagonist of the human PPARγ with an apparent IC
50 of 1 nM for the binding inhibition of rosiglitazone, a reference TZD. T0070907 covalently binds to Cys
313 of PPARγ, inducing conformational changes that block the recruitment of transcriptional cofactors to the PPARγ/RXR heterodimer.
6